Published February 2, 2021 | Version v1
Journal article Restricted

Tumor-Selective Immune Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil – Gold Nanoparticle Complexes

Authors/Creators

  • 1. CNRS Université Paris

Description

Peritoneal metastasis (PM) is considered as the terminal stage of metastatic colon cancer, with still poor median survival rate even with the best recent chemotherapy treatment. The current PM treatment combines cytoreductive surgery, which consists of resecting all macroscopic tumors, with hyperthermic intraperitoneal chemotherapy (HIPEC) which used mild hyperthermia to boost the diffusion and cytotoxic effect of chemotherapeutic drugs. As HIPEC is performed via a closed circulation of a hot liquid containing chemotherapy, it induces uncontrolled heating and drug distribution in the whole peritoneal cavity with important off-site toxicity and a high level of morbidity Here we propose a safer precision strategy using near-infrared (NIR) photo-activated gold nanoparticles (AuNPs) coupled to the chemotherapeutic drug 5-Fluorouracil (5-FU) to enable a spatial and temporal control of mild chemo-hyperthermia targeted to the tumor nodules within the peritoneal cavity. Both, the 16 nm AuNPs and the corresponding complex with 5-FU (AuNP-5-FU), were shown as efficient NIR photothermal agents in the microenvironment of subcutaneous colon tumor as well as PM in syngeneic mice. Noteworthy, NIR photothermia provided additional antitumor effects to 5-FU treatment. A single intraperitoneal administration of AuNP-5-FU resulted in their preferential accumulation in tumor nodules and peritoneal macrophages allowing light-induced selective hyperthermia, extended tumor necrosis, and activation of a pro-inflammatory immune response while leaving healthy tissues without any damage. From a translational standpoint, the combined and tumor targeted photothermal and chemotherapy mediated by the AuNP-drug complex has the potential to overcome the current off-target toxicity of HIPEC in clinical practice.

Files

Restricted

The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/6210427">Log in</a> to check if you have access.

Additional details

Funding

European Commission
NanoTBTech - Nanoparticles-based 2D thermal bioimaging technologies 801305
European Commission
NoCanTher - Nanomedicine upscaling for early clinical phases of multimodal cancer therapy 685795